Caldwell Sutter Capital
TVTX icon

Caldwell Sutter Capital’s Travere Therapeutics TVTX Stock Holding History

Caldwell Sutter Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-693
Closed -$39.4K – 971
2026
Q2 		$39.4K Buy
+693
New +$30.7K 0.01% 434

Other funds holding TVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Caldwell Sutter Capital's TVTX Position: Q3 2026 in Review

Caldwell Sutter Capital sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 693 shares — an estimated $39.4K sold.

Caldwell Sutter Capital first reported a position in TVTX in Q2 2026 and held it in 1 quarter. The position peaked at $39.4K in Q2 2026. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Caldwell Sutter Capital reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Caldwell Sutter Capital sold 693 Travere Therapeutics shares in Q3 2026, an estimated $39.4K.
  • Caldwell Sutter Capital first reported a position in Travere Therapeutics in Q2 2026 and held it in 1 quarter.
  • Caldwell Sutter Capital's Travere Therapeutics position peaked at $39.4K in Q2 2026.
  • 158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Caldwell Sutter Capital's 13F filing for Q3 2026, filed 9 Nov 2026.